Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekeres, Mikkael A., Montesinos, Pau, Novak, Jan, Wang, Jianxiang, Jeyakumar, Deepa, Tomlinson, Benjamin, Mayer, Jiri, Jou, Erin, Robak, Tadeusz, Taussig, David C., Dombret, Hervé, Merchant, Akil, Shaik, Naveed, O’Brien, Thomas, Roh, Whijae, Liu, Xueli, Ma, Wendy, DiRienzo, Christine G., Chan, Geoffrey, Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539167/
https://www.ncbi.nlm.nih.gov/pubmed/37604981
http://dx.doi.org/10.1038/s41375-023-02001-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539167/
https://www.ncbi.nlm.nih.gov/pubmed/37604981
http://dx.doi.org/10.1038/s41375-023-02001-z

Ejemplares similares